GlassScriptPhysician profile
Eric M Sieloff
NPI 1831627322
$4,006.61
in general payments reported to CMS, 2019-2025
17 companies · $46.34 in 2025
The $46.34 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $254 · 2022: $1,369 · 2023: $1,712 · 2024: $626 · 2025: $46.34.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,249 · Education: $135.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,248.64 |
| Education | $135.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $948.21 | 2021-2024 | Stelara, Tremfya |
| Abbvie INC. | $783.03 | 2021-2025 | Skyrizi, Rinvoq |
| E.R. Squibb & Sons, L.L.C. | $356.28 | 2022-2023 | Zeposia |
| Gilead Sciences, INC. | $315.90 | 2022-2024 | Epclusa |
| Janssen Scientific Affairs, LLC | $313.15 | 2021-2024 | Stelara |
| Regeneron Healthcare Solutions, INC. | $227.56 | 2022-2023 | Dupixent |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $157.44 | 2021-2023 | Plenvu, Xifaxan |
| Cook Medical LLC | $145.84 | 2023 | Fusion |
| Intercept Pharmaceuticals, INC. | $132.89 | 2022-2025 | |
| Ardelyx, INC. | $130.20 | 2023 | Ibsrela |
| Genzyme Corporation | $124.74 | 2024 | |
| Boston Scientific Corporation | $118.39 | 2023 | |
| Qol Medical, LLC | $107.10 | 2023 | Sucraid |
| Takeda Pharmaceuticals U.S.A., INC. | $91.33 | 2021-2024 | Entyvio |
| Astrazeneca Pharmaceuticals LP | $22.91 | 2023 | Andexxa |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celltrion USA INC. | $17.13 | 2024 | Zymfentra |
| Ferring Pharmaceuticals INC. | $14.51 | 2024 | Rebyota |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Sieloff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.